Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.54 |
| ▸ | KMO | O15229 | 1/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | KDM6B | O15054 | 1/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.50 |
| ▸ | KDM5C | P41229 | 1/20 | 0.50 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.50 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1329554 | 0.99 | XDH (0.53) | XDHKMOKDM4CKDM4EKDM6B | |
| SCHEMBL4446735 | 0.99 | XDH (0.53) | XDHKMOKDM4CKDM4EKDM6B | |
| SCHEMBL1331331 | 0.90 | XDH (0.55) | XDHKMOKDM4C | |
| SCHEMBL3387162 | 0.90 | KMO (0.56) | XDHKMOKDM4C | |
| SCHEMBL1329552 | 0.89 | XDH (0.45) | XDHKMOKDM4CKDM4AKDM5C | |
| SCHEMBL3383379 | 0.87 | XDH (0.55) | XDHKMOKDM4CKDM4EKDM6B | |
| SCHEMBL1330582 | 0.87 | KDM4E (0.52) | XDHKDM4CKDM4EKDM6BKDM5C | |
| SCHEMBL10092841 | 0.85 | XDH (0.57) | XDHKMOKDM4CKDM4E | |
| SCHEMBL1330401 | 0.84 | XDH (0.50) | XDHKMOKDM4CKDM4EKDM6B | |
| SCHEMBL1331700 | 0.83 | KDM4C (0.52) | XDHKMOKDM4CKDM4EKDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1992361-B1 | Remedy or preventive for digestive ulcer | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | claimed |
| US-8067446-B2 | Methods for treating an ulcer of the small intestine and stomach | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | claimed |
| EP-1932832-B1 | TRIARYLCARBOXYLIC ACID DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2010-12-01 | — | — | EP | claimed |
| US-7816558-B2 | Triarylcarboxylic acid derivative | ASTELLAS PHARMA INC. (JP) | 2010-10-19 | — | — | US | claimed |
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2009-02-05 | — | — | US | claimed |
| US-20090018104-A1 | Triarylcarboxylic Acid Derivative | ASTELLAS PHARMA INC. (JP) | 2009-01-15 | — | — | US | claimed |
| EP-1992361-A1 | REMEDY OR PREVENTIVE FOR DIGESTIVE ULCER | Astellas Pharma Inc. (JP) | 2008-11-19 | — | — | EP | claimed |
| EP-1932832-A1 | TRIARYLCARBOXYLIC ACID DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-06-18 | — | — | EP | claimed |
| US-8426453-B2 | Treatment of a stomach or small intestine ulcer with 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-1,3-thiazole-5-carboxylic acid | ASTELLAS PHARMA INC. (JP) | 2013-04-23 | — | — | US | disclosed |
| EP-1992361-B1 | Remedy or preventive for digestive ulcer | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8067446-B2 | Methods for treating an ulcer of the small intestine and stomach | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20110281919-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| EP-1932832-B1 | TRIARYLCARBOXYLIC ACID DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-7816558-B2 | Triarylcarboxylic acid derivative | ASTELLAS PHARMA INC. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20090018104-A1 | Triarylcarboxylic Acid Derivative | ASTELLAS PHARMA INC. (JP) | 2009-01-15 | — | — | US | disclosed |
| EP-1992361-A1 | REMEDY OR PREVENTIVE FOR DIGESTIVE ULCER | Astellas Pharma Inc. (JP) | 2008-11-19 | — | — | EP | disclosed |
| EP-1932832-A1 | TRIARYLCARBOXYLIC ACID DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | XDH, PEPD, HPN | XDH 1/4885KMO 1070/4885KDM4C 4654/4885 |
| US-20090018104-A1 | Triarylcarboxylic Acid Derivative | XDH, NLRP3, UACA | XDH 1/4885KMO 246/4885KDM4C 3563/4885 |
| US-20110281919-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | XDH, PEPD, HPN | XDH 1/4885KMO 1070/4885KDM4C 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.